IFAM
ESPR icon

Institutional & Family Asset Management’s Esperion Therapeutics ESPR Stock Holding History

Institutional & Family Asset Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-10
Closed -$1K – 849
2018
Q1 		$1K Buy
+10
New +$734 ﹤0.01% 779

Other funds holding ESPR

BB Biotech
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Pentwater Capital Management
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Credit Suisse
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Institutional & Family Asset Management's ESPR Position: Q2 2018 in Review

Institutional & Family Asset Management sold out of Esperion Therapeutics (ESPR) in Q2 2018, closing a stake of 10 shares — an estimated $1K sold.

Institutional & Family Asset Management first reported a position in ESPR in Q1 2018 and held it in 1 quarter. The position peaked at $1K in Q1 2018. 156 funds tracked by Wall St. Rank hold ESPR as of Q2 2018.

  • Institutional & Family Asset Management reported no remaining Esperion Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Institutional & Family Asset Management sold 10 Esperion Therapeutics shares in Q2 2018, an estimated $1K.
  • Institutional & Family Asset Management first reported a position in Esperion Therapeutics in Q1 2018 and held it in 1 quarter.
  • Institutional & Family Asset Management's Esperion Therapeutics position peaked at $1K in Q1 2018.
  • 156 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2018.

Based on Institutional & Family Asset Management's 13F filing for Q2 2018, filed 13 Aug 2018.